Skip to main content
SpringerLink
Log in

Triple-negatives Mammakarzinom

Längeres Gesamtüberleben durch zusätzliche Immuntherapie zur Standardchemotherapie

  • journal club
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Emens LA et al. JAMA Oncol. 2018; https://doi.org/10.1001/jamaoncol.2018.4224

  2. Schmid P et al. N Engl J Med. 2018;379(22):2108–21

    Article  CAS  Google Scholar 

  3. Emens LA, Middleton G. Cancer Immunol Res. 2015;3(5):436–43

    Article  CAS  Google Scholar 

  4. den Brok WD et al. Breast Cancer Res Treat. 2017;161(3):549–56

    Article  Google Scholar 

  5. Gobbini E et al. Eur J Cancer. 2018;96:17–24

    Article  Google Scholar 

Literatur

  • Schmid P et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22): 2108–21

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitäts-Frauenklinik Frankfurt am Main, Frankfurt am Main, Deutschland

    Christine Eichbaum

  2. HELIOS Dr. Horst-Schmidt-Kliniken Wiesbaden, Klinik für Gynäkologie und gynäkologische Onkologie, Wiesbaden, Deutschland

    Michael Eichbaum

Authors
  1. Christine Eichbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Eichbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christine Eichbaum.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eichbaum, C., Eichbaum, M. Längeres Gesamtüberleben durch zusätzliche Immuntherapie zur Standardchemotherapie. Info Onkol. 22, 28–29 (2019). https://doi.org/10.1007/s15004-019-6385-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-6385-4

Search

Navigation